Skip to main content
Premium Trial:

Request an Annual Quote

Digene Abandons Cytyc Merger, Citing FTC Anti-trust Threats

NEW YORK, July 1-Digene said today that it has terminated its merger with Cytyc, effective June 30.


Last week, the U.S. Federal Trade Commission said it would oppose the merger as a violation of anti-trust laws.


The two companies market screening tests for cervical cancer. Cytyc has the market-leading liquid Pap smear kit, and Digene offers the only FDA approved test for human papilloma virus, which is implicated in cervical cancer.


Cytyc announced its plans to acquire Digene in February 2002.


For further information, see the Digene website. ///issues/news//120495-1.html"

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.